Sarcoma Oncology Research Center | Santa Monica, CA

Research site
2811 Wilshire Boulevard, Suite 414, Santa Monica, California, United States of America
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site


18 of 50
Status: Active
Trial type: Interventional
Funder type: Industry

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Evaluate the safety and tolerability of sotorasib in adult subjects with KRAS p.G12C mutant advanced solid tumors.Estimate the maximum tolerated dose...

Active, not recruiting
KRAS p.G12C Mutant Advanced Solid Tumors
Drug: sotorasib
Drug: Anti PD-1/L1

The current study is designed to evaluate the efficacy and safety of AL102 in patients with progressive desmoid tumors.

Active, not recruiting
Desmoid Tumor
Drug: AL102
Other: Placebo

Part 1 is the dose escalation of APG-115 in combination with label dose of pembrolizumab.Part 2 is phase II design of APG-115 at recommended phase 2...

Mucosal Melanoma
P53 Mutation
Drug: APG-115+Pembrolizumab

This is a single-arm, non-randomized, open-label Phase 2 therapeutic study that will assess the effects of adding BPM31510 onto a conventional treatm...

Glioblastoma Multiforme
Drug: Temozolomide (TMZ)
Drug: BPM31510

An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in advanced or metastatic...

Active, not recruiting
Isocitrate Dehydrogenase Gene Mutation
Drug: HMPL-306

The primary objective of this study is to identify the recommended phase 2 dose (RP2D) and/or the maximum tolerated dose (MTD), and characterize the...

Advanced Solid Tumors
Drug: Gemcitabine
Drug: ADCT-601

This study will compare the efficacy and safety of unesbulin plus dacarbazine versus placebo plus dacarbazine in participants with unresectable or me...

Active, not recruiting
Drug: Dacarbazine
Drug: Unesbulin

Single agent, non-randomized, open label expansion in select sarcoma patients including myxoid liposarcoma and other sarcomas that share similar chro...

Active, not recruiting
Primary Pulmonary Myxoid Sarcoma
Sclerosing Epithelioid Fibrosarcoma
Drug: Seclidemstat
Drug: Cyclophosphamide

This is a multicenter open-label, randomized, non-comparative, parallel cohort pivotal study of treatment with envafolimab (cohort A and C) or envafo...

Undifferentiated Pleomorphic Sarcoma
Drug: Ipilimumab
Biological: Envafolimab

This study evaluates the safety and efficacy of AL3818 (anlotinib) hydrochloride in combination with Opdivo (nivilumab) for the treatment patients wi...

Active, not recruiting
Solid Tumor, Adult
Small Cell Lung Cancer
Drug: Nivolumab Injection
Drug: AL3818

Phase 1 is an open-label, multi-center dose escalation/dose expansion study designed to assess the safety, tolerability and pharmacokinetics (PK) for...

Active, not recruiting
Breast Cancer
Solid Tumor, Adult
Drug: Imx-110

This study evaluates nirogacestat (PF-03084014) in the treatment of desmoid tumor/aggressive fibromatosis (DT/AF). In the double-blind phase, half of...

Active, not recruiting
Aggressive Fibromatosis
Desmoid Tumor
Drug: Nirogacestat oral tablet
Drug: Placebo Oral Tablet

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic in...

Solid Tumor
Malignant Neoplasm
Drug: nab-sirolimus

The primary objective is to assess the safety and tolerability of Toripalimab in subjects with various advanced malignancies and to evaluate the reco...

Active, not recruiting
Advanced Malignancies
Biological: Toripalimab, Recombinant Humanized anti-PD-1 Monoclonal Antibody

This is an open label, dose-seeking phase 1/2 study using escalating doses of TRABECTEDIN given intravenously with defined doses of IPILIMUMAB and NI...

Metastatic Soft Tissue Sarcoma
Advanced Soft Tissue Sarcoma
Drug: Nivolumab
Drug: Ipilimumab

The primary objective is to evaluate the efficacy of SM-88, a combination metabolic cancer treatment, in two study cohorts:Clinically advanced Ewing'...

Active, not recruiting
Sarcoma, Ewing
Drug: Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS)

BBI-825 is a potent, selective, oral, small molecule inhibitor of ribonucleotide reductase (RNR). This is a first-in-human, open-label, non-randomize...

Solid Tumor
Drug: BBI-825

The participants of this study will have advanced epithelioid sarcoma. Sarcoma is a cancer of the connective tissues, such as nerves, muscles and bon...

Advanced Epithelioid Sarcoma
Advanced Soft-tissue Sarcoma
Drug: Placebo
Drug: Doxorubicin HCl

Trial conditions

Cancer (15 trials)
Sarcoma (14 trials)
Carcinoma (4 trials)
Liposarcoma (4 trials)
Breast Cancer (3 trials)
Chondrosarcoma (3 trials)
Ewing Sarcoma (3 trials)
Neoplasm Metastasis (3 trials)
Osteosarcoma (3 trials)
Pancreatic Cancer (3 trials)

And 43 more

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems